| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
TTA-Q6 is a selective antagonist of T-type Ca2+ channel and can be used in neurological research.
Animal models | WAG/Rij epilepsy model SD rat |
Preparation Method | To evaluate the effects of T-type antagonists on sleep and wake, telemetric recordings of electrocorticogram (ECoG) and electromyogram (EMG) signals were measured in rats. In a 7 day crossover design, vehicle or TTA-Q6 was dosed orally every day, 30 min before the inactive phase. The ECoG and EMG signals were collected and scored for the amount of time awake or each phase of sleep. |
Dosage form | 10 mg/kg TTA-Q6 orally every day for 7 days |
Applications | A 10 mg/kg dose of TTA-Q6 to rats right before their sleep period produced a further suppression of active wake for 0.5?2 h after dosing. |
| 产品描述 | TTA-Q6 is a selective antagonist of T-type Ca2+ channel and can be used in neurological research[1]. TTA-Q6 displayed good overall profiles and were examined in several in vivo assays responsive to T-type calcium channel antagonists. It showed robust inhibition of seizures in the WAG/Rij epilepsy model after oral dosing at 3 mg/kg. A 10 mg/kg dose of TTA-Q6 to rats right before their sleep period produced a further suppression of active wake for 0.5-2 h after dosing[2]. TTA-Q6 dose-dependently reduced amphetamine-induced psychomotor activity[3]. References: |
m.cnreagent.com